Danielle Charpentier

3.4k total citations
36 papers, 667 citations indexed

About

Danielle Charpentier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Danielle Charpentier has authored 36 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Otorhinolaryngology. Recurrent topics in Danielle Charpentier's work include Head and Neck Cancer Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Danielle Charpentier is often cited by papers focused on Head and Neck Cancer Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Danielle Charpentier collaborates with scholars based in Canada, United States and Australia. Danielle Charpentier's co-authors include Denis Soulières, Louis Guertin, Phuc Félix Nguyen‐Tan, B. Fortin, S. Matthews, Jean‐Claude Tabet, Manon Bélair, Louise Yelle, Michael Crump and Maureen Trudeau and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Danielle Charpentier

35 papers receiving 648 citations

Peers

Danielle Charpentier

ONCOL

PRM

OTORH

SURGE

Christine B. Boers‐Doets Netherlands

Marta Maddalo Italy

Yassine Lalami Belgium

Nuttapong Ngamphaiboon Thailand

Terence Rugg United Kingdom

Nancy B. Davis United States

Hung-Ming Wang Taiwan

Lorenzo Calvetti Italy

M. Veslemes Greece

Shang‐Yin Wu Taiwan

Christine B. Boers‐Doets Netherlands

Danielle Charpentier

432 ×1.1

ONCOL

372 ×1.6

PRM

178 ×0.9

OTORH

77 ×0.5

SURGE

114 ×0.8

Citations per year, relative to Danielle Charpentier Danielle Charpentier (= 1×) peers Christine B. Boers‐Doets

Countries citing papers authored by Danielle Charpentier

Since Specialization

Citations

This map shows the geographic impact of Danielle Charpentier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Charpentier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Charpentier more than expected).

Fields of papers citing papers by Danielle Charpentier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Charpentier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Charpentier. The network helps show where Danielle Charpentier may publish in the future.

Co-authorship network of co-authors of Danielle Charpentier

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle Charpentier. A scholar is included among the top collaborators of Danielle Charpentier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle Charpentier. Danielle Charpentier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahig, Houda, F. Aubin, Phuc Félix Nguyen‐Tan, et al.. (2023). Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.. Journal of Clinical Oncology. 41(16_suppl). 6050–6050. 1 indexed citations

Bahig, Houda, B. Fortin, Édith Filion, et al.. (2023). Predictors of prolonged treatment time intervals in oral cavity cancer. Oral Oncology. 147. 106622–106622. 2 indexed citations

Tehfé, Mustapha, et al.. (2021). 390MO Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada. Annals of Oncology. 32. S534–S534. 1 indexed citations

Bahig, Houda, F. Aubin, Phuc Félix Nguyen‐Tan, et al.. (2020). Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.. Journal of Clinical Oncology. 38(15_suppl). 6531–6531. 5 indexed citations

Roy, Claudie, Jean‐Philippe Adam, Franck Morin, et al.. (2018). Azacitidine-Induced Pyoderma Gangrenosum at Injection Sites in a Patient with Myelodysplastic Syndrome. Current Oncology. 25(1). 103–105. 3 indexed citations

Tehfé, Mustapha, Marie Florescu, Denis Soulières, et al.. (2015). Phase I and II studies of the decitabine–genistein drug combination in advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). e13556–e13556. 7 indexed citations

Lambert, Louise, B. Fortin, Denis Soulières, et al.. (2009). Organ Preservation With Concurrent Chemoradiation for Advanced Laryngeal Cancer: Are We Succeeding?. International Journal of Radiation Oncology*Biology*Physics. 76(2). 398–402. 51 indexed citations

Igidbashian, Levon, B. Fortin, Louis Guertin, et al.. (2009). Outcome With Neck Dissection After Chemoradiation for N3 Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 77(2). 414–420. 26 indexed citations

Clavel, S., David H. Nguyen, Philippe Després, et al.. (2009). Higher dose per fraction and shorter overall treatment time using intensity-modulated radiation therapy versus conventional radiation therapy with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma: A comparison of toxicity and efficacy. Journal of Clinical Oncology. 27(15_suppl). 6038–6038. 7 indexed citations

10.

Maroun, J., K. Bélanger, Lesley Seymour, et al.. (2006). Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Annals of Oncology. 17(9). 1371–1378. 51 indexed citations

11.

Forest, Véronique‐Isabelle, Phuc Félix Nguyen‐Tan, Jean‐Claude Tabet, et al.. (2006). Role of neck dissection following concurrent chemoradiation for advanced head and neck carcinoma. Head & Neck. 28(12). 1099–1105. 28 indexed citations

12.

Gélinas, Michel, Pierre Del Vecchio, Louis Guertin, et al.. (2006). Primary Radiotherapy for Tonsillar Carcinoma: A Good Alternative to a Surgical Approach. The Journal of Otolaryngology. 35(4). 227–227. 12 indexed citations

13.

Trudeau, Maureen, Michael Crump, Danielle Charpentier, et al.. (2006). Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). Annals of Oncology. 17(6). 952–956. 87 indexed citations

14.

Hirsh, Vera, Marie Duclos, Pierre Del Vecchio, et al.. (2005). Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in stage III non small cell lung cancer (NSCLC): Preliminary report. Journal of Clinical Oncology. 23(16_suppl). 7122–7122. 1 indexed citations

15.

Ayad, Tareck, Michel Gélinas, Louis Guertin, et al.. (2005). Retromolar Trigone Carcinoma Treated by Primary Radiation Therapy. Archives of Otolaryngology - Head and Neck Surgery. 131(7). 576–576. 20 indexed citations

16.

Hirsh, Vera, Denis Soulières, Marie Duclos, et al.. (2005). P-207 Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in Stage III non small cell lung cancer (NSCLC). Lung Cancer. 49. S169–S169. 2 indexed citations

17.

Bjarnason, Georg A., Danielle Charpentier, Ralph Wong, et al.. (2004). Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Investigational New Drugs. 23(1). 51–56. 1 indexed citations

18.

Hirsh, Vera, Renaud Whittom, Linda Ofiara, et al.. (2003). Weekly paclitaxel and gemcitabine chemotherapy for metastatic non‐small cell lung carcinoma (NSCLC). Cancer. 97(9). 2242–2247. 10 indexed citations

19.

Seiden, Michael V., Kenneth D. Swenerton, Ursula A. Matulonis, et al.. (2002). A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy. Gynecologic Oncology. 86(3). 302–310. 80 indexed citations

20.

Goss, Paul E., A. Keith Stewart, Félix Couture, et al.. (1999). Combined Results of Two Phase Il Studies of Taxol (Paclitaxel) in Patients with Relapsed or Refractory Lymphomas. Leukemia & lymphoma. 34(3-4). 295–304. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact